98168-52-6

Basic information

• Product Name: 1,3-DIELAIDIN
• Synonyms: DELTA 9 TRANS DIELAIDIN 1-3 ISOMER;C18:1,[TRANS]-9;1,3-DIELAIDIN;1,3-DI[TRANS-9-OCTADECENOYL]-GLYCEROL;1,3-DIELAIDIN (C18:1,-TRANS-9);1,3-Dielaidin,1,3-Di(trans-9-octadecenoyl)glycerol
• CAS NO: 98168-52-6
• Molecular Formula: C₃₉H₇₂O₅
• Molecular Weight: 620.99
• Mol File: 98168-52-6.mol
• Article Data: 36

Chemical Properties

• Boiling Point: 678.3°C at 760 mmHg
• Flash Point: 189.2°C
• Appearance: /
• Density: 0.934g/cm³
• Vapor Pressure: 2.58E-21mmHg at 25°C
• Refractive Index: 1.477
• Storage Temp.: −20°C
• CAS DataBase Reference: 1,3-DIELAIDIN(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-DIELAIDIN(98168-52-6)
• EPA Substance Registry System: 1,3-DIELAIDIN(98168-52-6)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 98168-52-6(Hazardous Substances Data)

Usage

Description

1,3-Dielaidoyl glycerol is a diacylglycerol that contains elaidic acid at the sn-1 and sn-3 positions.

Uses

1,3-Dielaidin is used to prepare symmetrical cationic triglycerides applicable to gene transfer.

InChI:InChI=1/C39H72O5/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(41)43-35-37(40)36-44-39(42)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,37,40H,3-16,21-36H2,1-2H3/b19-17+,20-18+

Upstream product

• 96-23-1 1,3-Dichloro-2-propanol 
• 143-19-1 sodium Oleate 
• 112-79-8 Elaidic Acid 
• 56-81-5 glycerol 
• 112-80-1 cis-Octadecenoic acid 
• 112-77-6 (Z)-9-octadecenoyl chloride 
• 62147-49-3 1,3-dihydroxyacetone dimer 
• 122-32-7 trioleoylglycerol 
• 112-62-9 Methyl oleate 
• 2716-53-2 1-mono[trans-9-octadecenoyl]-rac-glycerol 
• 24472-44-4 2-oxopropane-1,3-diyl dioleate 
• 111-62-6 oleic acid ethyl ester 
• 3896-58-0 vinyl oleate 
• 2442-61-7 1,2-dioleoylglycerol 

Downstream Products

• 1716-07-0 1,3-dioleoyl-2-palmitoylglycerol 
• 628-13-7 pyridine hydrochloride 
• 112-62-9 Methyl oleate 
• 148691-24-1 (Z,Z,Z,Z,Z)-icosa-5,8,11,14,17-pentaenoic acid 2-((Z)-octadec-9-enoyloxy)-1-((Z)-octadec-9-enoyloxymethyl)ethyl ester 
• 19229-69-7 Dioleo-β-lecithin 

Relevant articles and documents

Triglyceride-mimetic structure-gated prodrug nanoparticles for smart cancer therapy

Off-target drug release and insufficient drug delivery are the main obstacles for effective anticancer chemotherapy. Prodrug-based self-assembled nanoparticles bioactivated under tumor-specific conditions are one of the effective strategies to achieve on-demand drug release and effective tumor accumulation. Herein, stimuli-activable prodrugs are designed yielding smart tumor delivery by combination of the triglyceride-mimic (TG-mimetic) prodrug structure and disulfide bond. Surprisingly, these prodrugs can self-assemble into uniform nanoparticles (NPs) with a high drug loading (over 40%) and accumulate in tumor sites specifically. The super hydrophobic TG structure can act as a gate that senses lipase to selectively control over NP dissociation and affect the glutathione-triggered prodrug activation. In addition, the impacts of the double bonds in the prodrug NPs on parent drug release and the following cytotoxicity, pharmacokinetics, and antitumor efficiency are further demonstrated. Our findings highlight the promising potential of TG-mimetic structure-gated prodrug nanoparticles for tumor-specific drug delivery.

Stereospecific synthesis of phosphatidylglycerol using a cyanoethyl phosphoramidite precursor

Phosphatidylglycerols (PG) are a family of naturally occurring phospholipids that are responsible for critical operations within cells. PG are characterized by an (R) configuration in the diacyl glycerol backbone and an (S) configuration in the phosphoglycerol head group. Herein, we report a synthetic route to provide control over the PG stereocenters as well as control of the acyl chain identity.

LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.